Artificial Pancreas Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies 2024 [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
Countries, Regulatory Path and Key Companies, 2024 Update" report has been added to ResearchAndMarkets.com's offering. The Medical Devices sector report provides comprehensive information about the Artificial Pancreas pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Artificial Pancreas helps people with diabetes, primarily type 1, automatically and continuously control their blood glucose level by providing the substitute endocrine functionality of a healthy pancreas. Report Scope: Extensive coverage of the Artificial Pancreas under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects The coverage of pipeline products base
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte, Inc. (NASDAQ: HUMA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.MarketBeat
- Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024GlobeNewswire
- Humacyte, Inc. (NASDAQ: HUMA) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $4.00 price target on the stock.MarketBeat
- Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $15.00 price target on the stock.MarketBeat
- Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
HUMA
Earnings
- 3/22/24 - Beat
HUMA
Sec Filings
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- 3/28/24 - Form S-8
- HUMA's page on the SEC website